What is the difference between ARA-290 and Cortagen?

ARA-290: Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing Cortagen: Brain cortex-derived tetrapeptide that modulates gene expression in neural and cardiac tissue through chromatin regulatory mechanisms;

Is ARA-290 FDA approved?

ARA-290 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Cortagen FDA approved?

Cortagen is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is ARA-290 administered in research settings?

In research settings, ARA-290 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Cortagen administered in research settings?

In research settings, Cortagen is typically administered via the oral or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ARA-290 vs Cortagen

Peptide Comparison

ARA-290 vs Cortagen

Name: ARA-290 vs Cortagen — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Longevity & Cellular peptides.

ARA-290

Cibinetide

LongevityInvestigationalResearch Only

Half-life: ~2 min (IV); ~10–20 min (SC)

28 providers listed

Full ARA-290 profile →

Cortagen

vascular peptide bioregulator

LongevityNot EvaluatedResearch Only

5 providers listed

Full Cortagen profile →

Bottom line

ARA-290 carries stronger published evidence (RCT, 2 key studies) than Cortagen (Review, 2); both are research compounds.

Quick Verdict

ARA-290

Half-life

~2 min (IV); ~10–20 min (SC)

Cortagen

Half-life

—

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	ARA-290
Further along in FDA review	ARA-290
Oral administration option	Cortagen
More provider options (28 vs 5)	ARA-290

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

ARA-290

Cortagen

Mechanism Family

Longevity & Cellular

Half-life

~2 min (IV); ~10–20 min (SC)

—

FDA Status

investigational

not evaluated

Admin Routes

subcutaneous, intravenous

oral, subcutaneous

Availability

Research Only

Providers

28 listed

5 listed

Avail. Notes

Non-hematopoietic EPO analog (cibinetide) by Araim Pharma. Phase 3 for sarcoidosis peripheral neuropathy; Dutch conditional marketing authorisation applied for. No FDA approval. Investigational.

—

Research Evidence

ARA-290

RCT · 2 key studies · most recent 2026

Cortagen

Review · 2 key studies · most recent 2021

Research Citations

ARA-290

RCT2017 · Investigative Ophthalmology & Visual Science

Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients

Animal2026 · Neurobiol Dis

Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.

Cortagen

Animal2004 · Neuroendocrinology Letters

The effect of short peptides on the expression of genes in the cardiac muscle of old male rats

Review2021 · Molecules

Peptide Regulation of Gene Expression: A Systematic Review

About ARA-290

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

Research Areas

neuropathic pain relieftissue repairanti-inflammatorymetabolic improvement

About Cortagen

Brain cortex-derived tetrapeptide that modulates gene expression in neural and cardiac tissue through chromatin regulatory mechanisms; microarray analysis demonstrates broad transcriptional effects following administration.

Research Areas

neuroprotectiongene expression regulationlongevityanti-aging

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ARA-290

Reported (Unverified — Pending Clinical Review)

active erythrocytosis

No established clinical contraindications

Cortagen

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

ARA-290

$4.80/mg

$3.75 – $5.79 range

43 vendors

View price index →Find providers →

Cortagen

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

ARA-290

28 listed

Browse directory →

Providers offering

Cortagen

5 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated October 27, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ARA-290 vs Cortagen — Per-mg Price Comparison. Retrieved October 27, 2026, from https://peptidebase.io/peptides/compare/ara-290/cortagen

https://peptidebase.io/peptides/compare/ara-290/cortagen Methodology License Download JSON Download CSV